ALGS — Aligos Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1799448 ·
Last close
$1.36
Market Cap
$7.40M
52W High
$13.69
52W Low
$1.36
ADV30
60,191
Next earnings
2026-11-06

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,869,000 — -21,890,000 -21,860,000 47,189,000 31,094,000 35,883,000
Jun 2026 27,778,000 — -1,890,000 -1,504,000 66,327,000 30,381,000 34,443,000
Mar 2026 2,830,000 — -26,929,000 -23,040,000 64,558,000 29,980,000 32,769,000
Dec 2025 169,000 — -21,814,000 -19,881,000 88,533,000 18,303,000 34,988,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-94,168,000
Investing CF
$105,592,000
Financing CF
$228,000
CapEx
$-355,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-7.30
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-666,745,000
Inventory
—
Receivables
$27,778,000
ST Investments
$0
EBIT TTM
$-78,994,000
Pretax Income TTM
$-72,748,000
Interest Exp TTM
—
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$31,518,000
EBITDA
$-77,916,000
Free Cash Flow
$-61,390,248
Enterprise Value
$-1,461,649
Total Cash
$30,381,000
Total Debt
$3,504,000
Shares Out
5,444,558
Trailing EPS
$-6.46
Book Value
$8.67
ROE
-113.6%
ROA
-49.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,186,000 -87,985,000 -24,193,000 88,533,000 34,988,000 53,545,000 -82,503,000
Dec 2024 3,945,000 -89,154,000 -131,211,000 70,094,000 99,067,000 -28,973,000 -80,743,000
Dec 2023 15,529,000 -88,127,000 -87,679,000 151,527,000 59,447,000 92,080,000 -78,997,000
Dec 2022 13,907,000 -97,580,000 -96,046,000 146,693,000 42,793,000 103,900,000 -79,389,000

TTM Snapshot

Revenues TTM
$3,740,000
NetIncome TTM
$-75,962,000
OpCashFlow TTM
—
Assets (Latest)
$66,327,000
Forward EPS
$-5.25

Peers — same industry

TickerNameMarket CapLastDaily %
CUBT Curative Biotechnology Inc $7.56M $0.85 —
ZEOX Zeo ScientifiX, Inc. $6.27M $0.80 —
INTS INTENSITY THERAPEUTICS, INC. $8.81M $2.67 —
INAB IN8BIO, INC. $8.86M $0.82 —
TCRX TScan Therapeutics, Inc. $9.59M $0.15 —

News headlines (Yahoo Finance, 1h cache)

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
2026-11-06 13:00 · Yahoo
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
2026-11-05 21:05 · Yahoo
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026
2026-10-05 20:05 · Yahoo
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
2026-09-02 10:45 · Yahoo
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
2026-08-12 20:05 · Yahoo
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
2026-08-06 12:00 · Yahoo
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
2026-07-30 12:00 · Yahoo
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
2026-07-13 12:00 · Yahoo
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-24 12:00 · Yahoo
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
2026-05-13 06:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.